Long-term drug treatment for obesity: A systematic and clinical review

JAMA

Volumn 311, Issue 1, 2014, Pages 74-86

  Yanovski, Susan Z ^a   Yanovski, Jack A ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; BENZPHETAMINE; DOSPAN; LORCASERIN; METFORMIN; NALTREXONE; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENTERMINE RESIN; PLACEBO; QYSMIA; SEROTONIN RECEPTOR; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ANTIOBESITY AGENT;

ANXIETY DISORDER; BACKACHE; BODY MASS; CALORIC RESTRICTION; CARDIOMETABOLIC RISK; CLINICAL PRACTICE; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEFECATION DISORDER; DEFECATION URGENCY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; EXERCISE; FATIGUE; FECES INCONTINENCE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE TURBULENCE; HUMAN; HYPOGLYCEMIA; INSOMNIA; INTERVENTION STUDY; LIFESTYLE MODIFICATION; LIQUID FECES; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; MORTALITY; NAUSEA; NORADRENERGIC SYSTEM; OBESITY; OUTCOME ASSESSMENT; PARESTHESIA; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; RISK FACTOR; SPOTTING; SYSTEMATIC REVIEW; TASTE DISORDER; UNITED STATES; VOMITING; WEIGHT CONTROL; WEIGHT REDUCTION; XEROSTOMIA; LIFESTYLE; OFF LABEL DRUG USE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTI-OBESITY AGENTS; HUMANS; LIFE STYLE; OBESITY; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84891919414     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.281361     Document Type: Review

References (100)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012;82:1-8.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention ormetformin. N Engl J Med. 2002;346(6):393-403.
3. Ryan DH, Bray GA. Pharmacologic treatment options for obesity: what is old is new again. Curr Hypertens Rep. 2013;15(3):182-189.
4. Moyer VA; US Preventive Services Task Force. Screening for and management of obesity in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(5):373-378.
5. Carvajal R, Wadden TA, Tsai AG, Peck K, Moran CH. Managing obesity in primary care practice: a narrative review. Ann N Y Acad Sci. 2013;1281:191-206.
6. Wing RR, Lang W, Wadden TA, et al; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486.
7. Wadden TA, Volger S, Tsai AG, et al; POWER-UP Research Group. Managing obesity in primary care practice: an overview with perspective from the POWER-UP study. Int J Obes (Lond). 2013;37(suppl 1):S3-S11.
8. Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obesity Rev. 2012;13(6):509-517.
9. ABC Passport. Drug ABC list prices: Accessed by Richard Decederfelt, B.S.Pharm.,M.S.I.S. https://passport.amerisourcebergen.com/irj/portal. Accessed March 8, 2013.
10. US Dept of Health and Human Services. Prescription medications for the treatment of obesity: NIDDK weight-control information network fact sheet. NIH publication 07-4191 April 2013. http://win.niddk.nih.gov/publications/PDFs/ Prescription-Medications.pdf. Accessed September 25, 2013, 2013.
11. Roche Laboratories, Inc. XENICAL-orlistat capsule. Revised patient package insert January 2009. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/020766s026lbl.pdf. Accessed July 2, 2013.
12. Eisai Inc. BELVIQ (lorcaserin hydrochloride) tablets, for oral use. Patient package insert January 4, 2013. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/022529lbl.pdf. Accessed June 27, 2013.
13. Vivus Inc. Qsymia (phentermine and topiramate extended-release) capsules, for oral use. Patient package insert April 16, 2013. http://www.accessdata.fda. gov/drugsatfda-docs/label/2013/022580s004lbl.pdf. Accessed June 28, 2013.
14. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288-1294.
15. Sjöström L, Rissanen A, Andersen T, et al; European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352(9123):167-172.
16. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235-242.
17. Fine N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Dis. 2000;24(3):306-313.
18. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160-167.
19. Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000;248(3):245-254.
20. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G; European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8(1):49-61.
21. Broom I, Wilding J, Stott P, Myers N; UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract. 2002;56(7):494-499.
22. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2002;4(6):415-423.
23. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123-1128.
24. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Dis. 2003;27(5):591-597.
25. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161.
26. Berne C; Orlistat Swedish Type 2 Diabetes Study Group. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med. 2005;22(5):612-618.
27. Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab. 2005;7(3):254-262.
28. Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther. 2012;37(2):187-195.
29. Smith SR,Weissman NJ, Anderson CM, et al; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-256.
30. Fidler MC, Sanchez M, Raether B, et al; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-3077.
31. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426-1436.
32. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2): 330-342.
33. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
34. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Rel Metab Dis. 2003;27(12):1437-1446.
35. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546.
36. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194- 1199.
37. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755-1767.
38. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr. 2004;80(6):1461-1468.
39. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: ameta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14(5):383-392.
40. US Food and Drug Administration. Vivus, data on file: new drug application 022580: integrated summary of effectiveness, submitted October 17, 2011. Vivus Inc; 2011. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/ 022580Orig1s000OtherR.pdf. Accessed September 23, 2013.
41. Roberts MD. New Drug Application 22580: VI-0521 QNEXA (phentermine/topiramate). Sponsor: VIVUS. February 22, 2012. Table 7. US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee Meeting Clinical Briefing Document. Page 32. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisory Committee/UCM292315.pdf. Accessed September 21, 2013.
42. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26(2):262-273.
43. Colman E. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Circulation. 2012;125(17):2156-2164.
44. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-1418.
45. Hendricks EJ, Greenway FL,Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011;19(12):2351-2360.
46. Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States [published online ahead of print September 9, 2013]. Pharmacotherapy. 2013. doi:10.1002/phar.1342.
47. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1(5588):352-354.
48. Runyan JW Jr. Observations on the use of phendimetrazine, a new anorexigenic agent, in obese diabetics. Curr Ther Res Clin Exp. 1962;4:270-275.
49. Hadler AJ. Sustained-action phendimetrazine in obesity. J Clin Pharmacol J New Drugs. 1968;8(2):113-117.
50. Erdmann J, Lippl F, Klose G, Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment-efficacy and limitations. Aliment Pharmacol Ther. 2004;19(11):1173-1179.
51. Johansson K, Sundstrom J, Neovius K, Rossner S, Neovius M. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev. 2010;11(11):777-791.
52. Zhou YH, Ma XQ, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2012;7(6):e39062.
53. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistatmay be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord. 2001;25(7):1095-1099.
54. Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond). 2007;31(10):1567-1570.
55. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-588.
56. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577-1579.
57. Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). Am J Cardiol. 2013;111(8):1131-1138.
58. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308.
59. Margulis AV,Mitchell AA, Gilboa SM, et al Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207(5):405e1-405e7.
60. Vivus Inc. NDA 22580: QSYMIA (phentermine and topiramate extended-release) Capsules: risk evaluation and mitigation strategy (REMS): reference ID: 3294731, April 2013. http://www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/UCM312598. pdf. Accessed July 3, 2013.
61. Tran PT. Summaryminutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting, February 22, 2012. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisory Committee/UCM304401.pdf. Accessed July 3, 2013.
62. Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord. 1994;18(3):129-135.
63. LeBlanc E, O'Connor E, Whitlock EP, Patnode C, Kapka T. Screening for and Management of Obesity and Overweight in Adults. Report No.: 11-05159-EF-1. US Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
64. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731-737.
65. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35(7):1520-1530.
66. Gadde KM, Kopping MF,Wagner HR II, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med. 2012;172(20):1557-1564.
67. Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2011;13(2):169-180.
68. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring). 2010;18(9):1739-1746.
69. Tran PT, Thomas A; Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee. US Food and Drug Administration Center for Drug Evaluation and Research: December 7, 2010. http://www.fda.gov/downloads/ AdvisoryCommittees /CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisory Committee/UCM241508.pdf. Accessed July 3, 2013.
70. Orexigen Therapeutics Inc. Orexigen announces agreement from the FDA on a special protocol assessment for the Contrave Outcomes Trial. February 6, 2012. http://ir.orexigen.com /phoenix.zhtml?c=207034&p=irol-newsArticle &ID=1656731&highlight=. Accessed June 27, 2012.
71. Greenway FL, Fujioka K, Plodkowski RA, et al; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
72. Apovian CM, Aronne L, Rubino D, et al; COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-943.
73. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120.
74. Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on body weight: ameta-analysis [published online May 20, 2012]. Exp Diabetes Res. 2012. doi: 10.1155/2012/672658
75. Astrup A, Carraro R, Finer N, et al; NN8022-1807 Investigators. Safety, tolerability, and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [published online August 16, 2011]. Int J Obes (Lond). 2012. doi:10.1038/ijo.2011.158
76. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33(6):1173-1175.
77. Novo Nordisk. Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE-obesity and pre-diabetes: April 30, 2013. http://www.clinicaltrials.gov/ct2/show/ NCT01272219. Accessed July 5, 2013.
78. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The effects of exenatide (Byetta) on energy expenditure and weight loss in nondiabetic obese subjects:May 21, 2013. http://www.clinicaltrials.gov/ct2/show/ NCT00856609. Accessed July 5, 2013.
79. Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the SCALE Maintenance randomized study [published online September 3, 2013]. Int J Obes. 2013. doi: 10.1038/ijo.2013.148
80. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab. 2011;96(7):2027-2031.
81. Simons-Morton DG, Obarzanek E, Cutler JA. Obesity research-limitations of methods, measurements, and medications. JAMA. 2006;295(7):826-828.
82. Lauer MS. Lemons for obesity. Ann Intern Med. 2012;157(2):139-140.
83. Blanck HM, Khan LK, Serdula MK. Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. Prev Med. 2004;39(6):1243-1248.
84. Kahan S, Ferguson C, David S, Divine L. Obesity drug outcome measures: results of a multi-stakeholder critical dialoque. Current Obesity Reports. 2013;2(2):128-133. doi:10.1007/s13679-013-0052-0
85. Rissanen A, Lean M, Rössner S, Segal KR, Sjöström L. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes RelatMetab Disord. 2003;27(1):103-109.
86. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab. 2006;8(2):206-213.
87. Golden J. US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee clinical briefing document May 10, 2012. Arena Pharmaceuticals, Inc. New Drug Application 022529: Lorcaserin hydrochloride tablets 10mg. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisory Committee/UCM303198.pdf. Accessed October 5, 2013.
88. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf. 2005;4(6):1083-1095.
89. Wing RR, Bolin P, Brancati FL, et al; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154.
90. Tran PT, Thomas A. Summary minutes of the Endocrinologic and Metabolic Drugs Advisory Committee meeting March 28-29, 2012. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303352.pdf. Accessed July 3, 2013.
91. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111- 2120.
92. Garber AJ, Abrahamson MJ, Barzilay JI, et al AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2):327-336.
93. Wadden TA,West DS, Neiberg RH, et al; Look AHEAD Research Group. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4): 713-722.
94. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. II (weeks 34 to 104). an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51(5):595-601.
95. Silverstone T. Intermittent treatment with anorectic drugs. Practitioner. 1974;213(1274): 245-252.
96. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999;69(6):1108-1116.
97. Garvey WT. New tools for weight loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. Endocr Pract. 2013;19(5):864-874.
98. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259-1272.
99. Gadde KM, Allison DB. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother. 2009;10(6):921-925.
100. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring). 2009;17(9):1730-1735.